Lansoprazole Bgr

Lansoprazole, the active ingredient in Lansoprazole Bgr, is a proton pump inhibitor presented as a generic oral tablet for oral use. It reduces gastric acid production and is employed in the management of acid‑related gastrointestinal conditions such as GERD, erosive esophagitis, duodenal ulcer and Helicobacter pylori eradication regimens.

GNH USA supplies Lansoprazole Bgr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion, making it useful for several acid‑related gastrointestinal disorders.

- Gastro‑esophageal reflux disease (GERD): alleviates heartburn and regurgitation by maintaining a higher gastric pH. - Erosive esophagitis: promotes healing of damaged esophageal lining by decreasing acid exposure. - Duodenal ulcer: supports ulcer resolution and prevents recurrence through acid suppression. - Helicobacter pylori eradication: enhances the effectiveness of antibiotic regimens by creating a less acidic gastric environment.

Lansoprazole may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild headache reported in some patients. - Diarrhea: loose stools occurring during therapy. - Nausea: feeling of queasiness or upset stomach. - Abdominal pain: discomfort or cramps in the abdomen. - Flatulence: increased intestinal gas. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Low magnesium levels: hypomagnesemia causing muscle cramps or irregular heartbeat. - Bone fractures: increased risk of hip, wrist or spine fractures with long‑term use. - Acute interstitial nephritis: kidney inflammation presenting with fever and rash.

When prescribing or dispensing Lansoprazole, several safety considerations should be observed to minimize risks.

- Assess renal function: dose adjustment may be needed in severe renal impairment. - Review concomitant medications: potential interactions can affect drug levels. - Monitor for infection: prolonged acid suppression may increase risk of gastrointestinal infections. - Evaluate bone health: long‑term use may be linked to decreased calcium absorption. - Counsel on symptom monitoring: report persistent abdominal pain or vomiting. - Store at ambient temperature: keep below 25°C in the original container, protected from moisture.

Lansoprazole can affect the pharmacokinetics of several co‑administered drugs, requiring attention to interaction potential.

Major Interactions (Avoid): - Antifungal azoles (ketoconazole, itraconazole): reduced absorption due to increased gastric pH. - HIV protease inhibitors (atazanavir, nelfinavir): decreased efficacy when gastric pH is elevated. - Clopidogrel: reduced activation leading to diminished antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation parameters. - Methotrexate: reduced renal clearance, monitor serum levels. - Digoxin: slight increase in serum concentration, observe for toxicity.